Clinical Trials | May 02, 2023
Lilly's Lebrikizumab shows improved face or hand dermatitis
Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients
Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients
The agreement between Eli Lilly and Janssen was established to allow the two companies to share resources for the goal of accelerating the evaluation of the respective companies’ assets, mirikizumab and Tremfya (guselkumab).
Alopecia areata usually presents as a few small bald patches in the head
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
Under the terms of the agreement, Bachem will provide the appropriate engineering infrastructure and expertise to implement Lilly’s novel oligonucleotide manufacturing technology
Lilly may be eligible for up to US $ 225m in payments based upon the achievement of pre-specified development, regulatory and commercial milestones
Bebtelovimab neutralizes Omicron as demonstrated by pseudo virus and authentic virus data
The tie-up combines Abbisko Therapeutics’ proprietary drug discovery platform with Lilly’s disease and discovery expertise
Entos will receive an initial payment of US $50 million, which includes an equity investment by Lilly
Subscribe To Our Newsletter & Stay Updated
